Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001753926-25-000790
Filing Date
2025-05-13
Accepted
2025-05-13 16:31:08
Documents
59
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q g084808_10q.htm   iXBRL 10-Q 1204422
2 EXHIBIT 10.10 g084808_ex10-10.htm EX-10.10 31507
3 EXHIBIT 10.11 g084808_ex10-11.htm EX-10.11 14416
4 EXHIBIT 31.1 g084808_ex31-1.htm EX-31.1 7740
5 EXHIBIT 32.1 g084808_ex32-1.htm EX-32.1 4141
11 GRAPHIC img001_v1.jpg GRAPHIC 48379
12 GRAPHIC img002_v1.jpg GRAPHIC 48084
13 GRAPHIC img003_v3.jpg GRAPHIC 195985
14 GRAPHIC img004_v3.jpg GRAPHIC 194439
  Complete submission text file 0001753926-25-000790.txt   6571816

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE chro-20250331.xsd EX-101.SCH 46250
7 XBRL CALCULATION FILE chro-20250331_cal.xml EX-101.CAL 32246
8 XBRL DEFINITION FILE chro-20250331_def.xml EX-101.DEF 128621
9 XBRL LABEL FILE chro-20250331_lab.xml EX-101.LAB 383725
10 XBRL PRESENTATION FILE chro-20250331_pre.xml EX-101.PRE 259809
62 EXTRACTED XBRL INSTANCE DOCUMENT g084808_10q_htm.xml XML 887713
Mailing Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902
Business Address 685 US HIGHWAY ONE NORTH BRUNSWICK NJ 08902 9176446313
Channel Therapeutics Corp (Filer) CIK: 0001919246 (see all company filings)

EIN.: 863335449 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41964 | Film No.: 25940664
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)